Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
bullish
Medlive Technology
Watchlist
Medlive - High Conviction Update 2022
Equity Bottom-Up
370 Views
05 Apr 2022 06:18
Medlive is currently trading at a FY2 EV/Revenue of 0.97x and we think Medlive’s shares are extremely cheap at the current valuation and offers a good entry point.
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart
(Sign Up to Access)
Insight Stream
Takeda 4QFY22: Top Line Expands and Pipeline Development Progresses Despite OP Drop
12 May 2022
OneConnect Files for Secondary Listing; Not Yet a Convincing Story
07 Apr 2022
Takeda Strengthens Rare Disease Portfolio Through Tie-Ups with Gene Therapy Developers
06 Apr 2022
M3: Covid Related Trials and Vaccination Programs Drive Earnings; Core Business Growth Slowing Down
02 Feb 2022
2022 High Conviction – Medlive: Key Beneficiary of Digital Healthcare Marketing in China
08 Dec 2021
Medlive IPO: Thoughts on First Day Trading
14 Jul 2021
Top
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.54.9
x